104 related articles for article (PubMed ID: 8797577)
1. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
Liggett WH; Sewell DA; Rocco J; Ahrendt SA; Koch W; Sidransky D
Cancer Res; 1996 Sep; 56(18):4119-23. PubMed ID: 8797577
[TBL] [Abstract][Full Text] [Related]
2. Familial head and neck cancer: molecular analysis of a new clinical entity.
Yu KK; Zanation AM; Moss JR; Yarbrough WG
Laryngoscope; 2002 Sep; 112(9):1587-93. PubMed ID: 12352668
[TBL] [Abstract][Full Text] [Related]
3. A novel p16INK4A transcript.
Mao L; Merlo A; Bedi G; Shapiro GI; Edwards CD; Rollins BJ; Sidransky D
Cancer Res; 1995 Jul; 55(14):2995-7. PubMed ID: 7541708
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
7. Effects of exogenous p16INK4a on growth of cells with various status of cell-cycle regulators.
Suzuki-Takahashi I; Higashi H; Yoshida E; Nishimura S; Kitagawa M
Biochem Biophys Res Commun; 1997 May; 234(2):386-92. PubMed ID: 9177281
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.
Schreiber M; Muller WJ; Singh G; Graham FL
Oncogene; 1999 Mar; 18(9):1663-76. PubMed ID: 10208428
[TBL] [Abstract][Full Text] [Related]
9. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma.
Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D
Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532
[TBL] [Abstract][Full Text] [Related]
11. Complex structure and regulation of the P16 (MTS1) locus.
Stone S; Jiang P; Dayananth P; Tavtigian SV; Katcher H; Parry D; Peters G; Kamb A
Cancer Res; 1995 Jul; 55(14):2988-94. PubMed ID: 7606716
[TBL] [Abstract][Full Text] [Related]
12. Deletion of p16INK4A/CDKN2 and p15INK4B in human somatic cell hybrids and hybrid-derived tumors.
Kuerbitz SJ; Malandro J; Compitello N; Baylin SB; Graff JR
Cell Growth Differ; 1999 Jan; 10(1):27-33. PubMed ID: 9950215
[TBL] [Abstract][Full Text] [Related]
13. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
14. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.
Reed AL; Califano J; Cairns P; Westra WH; Jones RM; Koch W; Ahrendt S; Eby Y; Sewell D; Nawroz H; Bartek J; Sidransky D
Cancer Res; 1996 Aug; 56(16):3630-3. PubMed ID: 8705996
[TBL] [Abstract][Full Text] [Related]
15. Deletion of P15 (MTS2) in head and neck squamous cell carcinomas.
Roesler JM; Livingston EH; Srivatsan E; Chang P; Wang MB
J Surg Res; 1998 Jun; 77(1):50-4. PubMed ID: 9698532
[TBL] [Abstract][Full Text] [Related]
16. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.
Zariwala M; Xiong Y
Oncogene; 1996 Nov; 13(9):2033-8. PubMed ID: 8934552
[TBL] [Abstract][Full Text] [Related]
17. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
18. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer.
Rocco JW; Li D; Liggett WH; Duan L; Saunders JK; Sidransky D; O'Malley BW
Clin Cancer Res; 1998 Jul; 4(7):1697-704. PubMed ID: 9676844
[TBL] [Abstract][Full Text] [Related]
19. Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines.
Costanzi-Strauss E; Strauss BE; Naviaux RK; Haas M
Exp Cell Res; 1998 Jan; 238(1):51-62. PubMed ID: 9457056
[TBL] [Abstract][Full Text] [Related]
20. Effect of p16INK4a on chemosensitivity in nasopharyngeal carcinoma cells.
Chow LS; Wang X; Kwong DL; Sham JS; Tsao SW; Nicholls JM
Int J Oncol; 2000 Jul; 17(1):135-40. PubMed ID: 10853030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
